2 Strain Blend

ATCC SD5221 x LAFT1

JUMP TO:
01
Summary

A double-blind, placebo-controlled trial evaluated the effects of this 2-strain probiotic blend in an adult IBS population.(1) Despite being of decent quality, the study was statistically underpowered. Regardless, the probiotic appeared to be superior to placebo in improving flatulence scores and the composite symptom score categorized under “global IBS symptoms.” No significant differences were observed between the probiotic and placebo groups for stool frequency, consistency, bloating scores, abdominal pain scores, or the symptom of “rumbling.”

Key Takeaway:

An underpowered but otherwise decent quality study found improvements in flatulence scores and a composite symptom score for this 2-strain probiotic. While this probiotic may have therapeutic potential for IBS, more well-conducted and sufficiently powered studies are needed to confirm its benefits.

Dose: 

Dose 10 billion CFU taken as two 5 billion CFU capsules per day, one in the morning and one in the evening 30 minutes before a meal with a full glass of water. 
Form Capsules 
Suggested Minimum 

Trial Duration

 8 weeks

 

Reference:

  1. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liv Dis 2020;52:534-540. [doi: 10.1016/j.gld.2019.12.009] 
Read More…

A double-blind, placebo-controlled trial evaluated the effects of this 2-strain probiotic blend in an adult IBS population.(1) Despite being of decent quality, the study was statistically underpowered. Regardless, the probiotic appeared to be superior to placebo in improving flatulence scores and the composite symptom score categorized under “global IBS symptoms.” No significant differences were observed between the probiotic and placebo groups for stool frequency, consistency, bloating scores, abdominal pain scores, or the symptom of “rumbling.”

Key Takeaway:

An underpowered but otherwise decent quality study found improvements in flatulence scores and a composite symptom score for this 2-strain probiotic. While this probiotic may have therapeutic potential for IBS, more well-conducted and sufficiently powered studies are needed to confirm its benefits.

Dose: 

Dose 10 billion CFU taken as two 5 billion CFU capsules per day, one in the morning and one in the evening 30 minutes before a meal with a full glass of water. 
Form Capsules 
Suggested Minimum 

Trial Duration

 8 weeks

 

Reference:

  1. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liv Dis 2020;52:534-540. [doi: 10.1016/j.gld.2019.12.009] 
Read More…
Find a probiotic with ATCC SD5221 x LAFT1

Evaluate products based on whether they transparently disclose all ingredients and their amounts, exclusively use probiotics tested in randomized placebo-controlled trials in IBS populations, and contain studied doses.

View products containing this strain

A double-blind, placebo-controlled trial evaluated the effects of this 2-strain probiotic blend in an adult IBS population.(1) Despite being of decent quality, the study was statistically underpowered. Regardless, the probiotic appeared to be superior to placebo in improving flatulence scores and the composite symptom score categorized under “global IBS symptoms.” No significant differences were observed between the probiotic and placebo groups for stool frequency, consistency, bloating scores, abdominal pain scores, or the symptom of “rumbling.”

Key Takeaway:

An underpowered but otherwise decent quality study found improvements in flatulence scores and a composite symptom score for this 2-strain probiotic. While this probiotic may have therapeutic potential for IBS, more well-conducted and sufficiently powered studies are needed to confirm its benefits.

Dose: 

Dose 10 billion CFU taken as two 5 billion CFU capsules per day, one in the morning and one in the evening 30 minutes before a meal with a full glass of water. 
Form Capsules 
Suggested Minimum 

Trial Duration

 8 weeks

 

Reference:

  1. Sadrin S, Sennoune S, Gout B, et al. A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial. Dig Liv Dis 2020;52:534-540. [doi: 10.1016/j.gld.2019.12.009] 
02
Results
Overall evidence quality grade
90%

This probiotic has higher quality studies in IBS populations supporting it. View our evidence evaluation framework to learn how we assess the quality of studies.

Refine by Probiotic(s) In this view, show results

Close
  • Where trash
    trash

Add condition

03
Patient Handout
Share
Download
04
Clinical Studies
  • #
  • Study
  • Year
  • Author(s)
  • Journal
  • Reference
  • Daily Dose
  • Duration of Intervention
  • Form
  • Study Design
  • Age
  • Participants
    • Study #1

    • A 2-strain mixture of Lactobacillus acidophilus in the treatment of irritable bowel syndrome: A placebo-controlled randomized clinical trial

    • 2020
    • Sudha MR, Jayanthi N, Aasin M, et al.

    • Dig Liv Dis 2020;52:534-540

    • DOI: 10.1016/j.gld.2019.12.009
    • 10 billion CFU
    • 8 weeks
    • Capsule
      • RANDOMIZED
      • DOUBLE-BLIND
      • PLACEBO-CONTROLLED
      • PARALLEL GROUP
      • MULTICENTER

    • ADULTS

    • n=80; placebo n= 40; probiotic n= 40
      ITT,PP (total) n=80,75
      ITT,PP (probiotic) n=40,38
      ITT,PP (placebo) n=40,37
05
Findings from studies

#

  • Diarrhea
  • Constipation
  • Bowel Habits
  • Global IBS Symptoms
  • Abdominal Pain / Discomfort
  • Bloating / Distention
  • Gas / Flatulence
  • Nausea / Vomiting
  • Mental Health
  • Quality of Life
  • Miscellaneous Symptoms
  • Notes

  • Study #1

    • Diarrhea

      • No data

    • Constipation

      • No data

    • Bowel Habits

      • No significant differences between groups were observed for stool frequency (P = 0.73) and consistency (P = 0.89) at the end of the trial

    • Global IBS Symptoms

      • Significant differences between groups were found for composite scores at week 8 (79.2 ± 9.6 vs 103.7 ± 9.8, in probiotics and placebo groups respectively; LS Means differences = 24.54 ± 11.84; P = 0.04). The composite score was the sum of 4 VAS scores (abdominal pain/discomfort, bloating, flatus and rumbling) calculated for each patient.

    • Abdominal Pain / Discomfort

      • Abdominal pain score was significantly improved in both groups at weeks 4 and 8 (P < 0.0001), but no significant differences were found between groups at week 8 (19.0 ± 2.5 vs 25.1 ± 2.6, respectively; LS Means differences = 6.0 ± 3.2; P = 0.06).

    • Bloating / Distention

      • Bloating scores improved significantly in both groups (P < 0.0001) after 8 weeks of treatment compared with baseline, but no significant differences between groups were found at week 8 (20.7 ± 2.8 vs 26.3 ± 2.8, in probiotics and placebo groups respectively; LS Means differences = 5.6 ± 3.5; P = 0.10)

    • Gas / Flatulence

      • Significant differences between groups were found for flatus scores at week 4 (28.3 ± 3.0 vs 36.0 ± 3.1, in probiotics and placebo groups respectively; LS Means differences = 7.7 ± 3.7; P = 0.04) and week 8 (21.3 ± 3.0 vs 29.6 ± 3.1, in probiotics and placebo groups respectively; LS Means differences = 8.2 ± 3.8; P = 0.03).

    • Nausea / Vomiting

      • No data

    • Mental Health

      • No data

    • Quality of Life

      • No data

    • Miscellaneous Symptoms

      • For the symptom of “rumbling” there were no significant differences between the probiotic and placebo group (p=0.21)

    • Notes

      • No data